Hepatitis C Virus: No Longer a Barrier to Oncology Care

Sobia N. Laique; Hugo E Vargas

doi:10.14309/ajg.0000000000000095

Hepatitis C Virus: No Longer a Barrier to Oncology Care

Sobia N. Laique, Hugo E Vargas

Hepatology

Research output: Contribution to journal › Article › peer-review

Abstract

Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

Original language	English (US)
Pages (from-to)	207-208
Number of pages	2
Journal	The American Journal of Gastroenterology
Volume	114
Issue number	2
DOIs	https://doi.org/10.14309/ajg.0000000000000095
State	Published - Feb 1 2019

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.14309/ajg.0000000000000095

Cite this

@article{ceb65f003ba341f88ec5849aa353d3e9,

title = "Hepatitis C Virus: No Longer a Barrier to Oncology Care",

abstract = "Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.",

author = "Laique, {Sobia N.} and Vargas, {Hugo E}",

year = "2019",

month = feb,

day = "1",

doi = "10.14309/ajg.0000000000000095",

language = "English (US)",

volume = "114",

pages = "207--208",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Hepatitis C Virus

T2 - No Longer a Barrier to Oncology Care

AU - Laique, Sobia N.

AU - Vargas, Hugo E

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

AB - Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

UR - http://www.scopus.com/inward/record.url?scp=85061147130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061147130&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000000095

DO - 10.14309/ajg.0000000000000095

M3 - Article

C2 - 30676362

AN - SCOPUS:85061147130

SN - 0002-9270

VL - 114

SP - 207

EP - 208

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 2

ER -

Hepatitis C Virus: No Longer a Barrier to Oncology Care

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this